AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. Based on vaccination technologies created at the Rega Institute and launched in 2022, AstriVax is a privately held spin-off firm from KU Leuven. AstriVax is developing a first-of-its-kind Plug & Play vaccination platform using patented DNA-based technology that releases live attenuated viruses that self-amplify. An extensive range of vaccines for the prevention and treatment of infectious illnesses can be created using the flexible technology of AstriVax.
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. Based on vaccination technologies created at the Rega Institute and launched in 2022, AstriVax is a privately held spin-off firm from KU Leuven. AstriVax is developing a first-of-its-kind Plug & Play vaccination platform using patented DNA-based technology that releases live attenuated viruses that self-amplify. An extensive range of vaccines for the prevention and treatment of infectious illnesses can be created using the flexible technology of AstriVax.
